Brief: Matinas BioPharma Announces DSMB Approval To Commence Part 2 Of Enact Study Of MAT2203 For Treatment Of Cryptococcal Meningitis

Matinas BioPharma Holdings

19/02/2020 12:32

Feb 19 (Reuters) - Matinas BioPharma Holdings Inc  MTNB.A :
    * MATINAS BIOPHARMA ANNOUNCES DSMB APPROVAL TO COMMENCE PART
2 OF
ENACT STUDY OF MAT2203 (ORAL AMPHOTERICIN B) FOR TREATMENT OF
CRYPTOCOCCAL MENINGITIS
    * MATINAS BIOPHARMA - PART 2 EFFICACY PORTION OF ENACT
EXPECTED TO
COMMENCE Q1 2020

Source text for Eikon:  ID:nGNX85vm5B 
Further company coverage:  MTNB.A 

 ((Reuters.Briefs@thomsonreuters.com;))